The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell l
Authors
Georg Heß (ORCID: https://orcid.org/0000-0002-9282-5688)
Anke Ohler (ORCID: https://orcid.org/0000-0002-4036-4744)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell l
Georg Heß, Anke Ohler, Susanne Singer, Eva Hoster et al.
Local Database Links
1 links
Journal
BMC Cancer
Topics
Lymphoma Diagnosis and Treatment
article
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell l
Georg Heß, Anke Ohler, Susanne Singer, Eva Hoster, Elisabeth Hoenig, Martin Dreyling, Stephanie Herold, Alessandra Tucci, Marco Ladetto, Christian Schmidt, Carlo Visco, Marie‐Kristin Tilch, Michael Unterhalt, Christiane Pott
article en
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
University of Verona (IT), Johannes Gutenberg University Mainz (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Zimmer Biomet (Germany) (DE), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), University Hospital Schleswig-Holstein (DE), Rostock University of Music and Theatre (DE), Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT), Ludwig-Maximilians-Universität München (DE), University of Lübeck (DE)
Funders
Universitätsmedizin der Johannes Gutenberg-Universität Mainz